Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00151996 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: Methylphenidate + SPD503 (Guanfacine hydrochloride)
DRUG: Amphetamine + SPD503

Sponsor

Shire